<!doctype html public "-//W3C//DTD W3 HTML//EN">
<html><head><style type="text/css"><!--
blockquote, dl, ul, ol, li { padding-top: 0 ; padding-bottom: 0 }
--></style><title>BMES Distinguished Lecture
Series</title></head><body>
<blockquote type="cite" cite>From:</blockquote>
<blockquote type="cite" cite>Chensi Ouyang</blockquote>
<blockquote type="cite" cite><br></blockquote>
<blockquote type="cite" cite>I am the co-Vice President of Special
Programs in the Bio-medical Engineering Society. BMES will be
hosting a lecture on October 12 as part of our monthly Distinguished
Lecture Series. The speaker is Dr. Can Ozbal, who used to be a
graduate student at MIT and now is a program manager at BioTrove Inc.
He will be speaking about the development of RapidFire (tm) MS
interface for mass spectroscopy. </blockquote>
<blockquote type="cite" cite><br></blockquote>
<blockquote type="cite"
cite>--------------------------------------------------------<br>
<br>
The Biomedical Engineering Society (BMES) invites you to attend our
Distinguished Lecture Series on October 12th, with Dr. Ozbal of
Biotrove, Inc. as our distinguished speaker.<br>
<br>
************************************************<br>
Wednesday. October 12, 2005.<br>
Refreshments at 6:30 pm.<br>
Lecture at 7:00 pm.<br>
Room 66-110.<br>
------------------------------------------------<br>
<br>
<b>High-Throughput Mass Spectrometry: From Concept to
Commercialization<br>
<br>
</b>Can C. Özbal, Ph.D.<br>
Program Manager, RapidFire" Lead Discovery<br>
BioTrove Inc.<br>
<br>
------------------------------------------------<br>
<br>
Mass spectrometry (MS) is a powerful analytical tool that has the
ability to quantify selected analytes based on molecular weight.
As such, MS has become a widely used tool in many phases of drug
development, ranging from target discovery and validation through lead
optimization and biomarker discovery. One limitation of the use
of mass spectrometry is the incompatibility of the method with samples
that contain non-volatile components, such as salts and buffers, due
to ion suppression and precipitation in the MS ion source.
Analysis of such samples requires an initial chromatography step that
is typically the rate-limiting factor on MS throughput. BioTrove
has developed the RapidFireTM MS interface that enables sustained
throughputs of MS systems at 4 to 8 seconds per sample, enabling the
use of mass spectrometry in primary screening for lead compound
identification. The talk will focus on the technology and its
commercialization. <br>
<br>
After receiving an A.B. in chemistry with honors from Bowdoin College,
Dr. Ozbal joined the laboratory of Steven Tannenbaum at M.I.T. where
he earned his Ph.D. in Toxicology. His doctoral work involved
the quantification of DNA and protein adducts of a class of
environmental carcinogens known as polycyclic aromatic hydrocarbons
and required the development of new instrumentation and
ultra-sensitive analytical methods. After graduation Dr. Özbal
stayed on at M.I.T. as an instructor where he was involved in the
teaching of undergraduate level lecture and laboratory courses.
Dr. Özbal left M.I.T. to join BioTrove as one of its first employees
where he was responsible for much of the RapidFire technology
development, including the ultra high throughput mass spectrometry
interface. Currently he is the manager of the RapidFire business
unit at BioTrove and is involved in both commercial and scientific
operations.<br>
<br>
<br>
************************************************<br>
co-sponsored by the IEEE EMBS, Boston Chapter.</blockquote>
<div><br></div>
</body>
</html>